The RBC Rules Changed. What Should Insurers and Captives Do Now?

The short answer: in June 2026 the NAIC moved from deliberation to adoption, since ratified by the full NAIC at its August 2026 Summer National Meeting. New risk-based capital treatment for collateral loans (effective year-end 2027) and new C-1 factors for CLOs (effective year-end 2026) replace flat, label-based charges with charges that follow the economics of each structure. The work now is practical: inventory what you hold, assemble the data that earns the relief, forecast under both effective dates, and re-ask your reinsurance counterparties what the changes do to them. This is Part I of the Capital Credibility Series — understanding the next generation of insurance capital, collateral and reinsurance oversight.

What changed, in one paragraph

For collateral loans, a single flat 6.8% pre-tax charge has been replaced, for the main collateral categories, by treatment based on what actually secures the loan; the 6.8% charge is retained as the default for other collateral loans and for mortgage-backed loans without loan-level detail. Loans backed by mortgages look through to mortgage factors. Loans backed by fund interests — joint ventures, limited partnerships, LLCs — start at a 30% base charge; loans backed by residual tranches start at 45%. Both can earn substantial relief, scaling with demonstrated overcollateralization up to a 50% reduction where collateral coverage reaches twice the loan balance — but no relief at all where loan-to-value exceeds 90%, and none without independent fair-value verification of the collateral. For CLOs, residual tranches keep their 45% charge, and thin below-investment-grade tranches of broadly syndicated deals now attract a meaningful surcharge, measured against the most recent trustee report.

Notice the design principle running through both changes: capital treatment now follows the economics of the structure, not its legal label. That principle is the theme of this series, and it is not finished with collateral loans.

Start with an honest inventory

The first task is unglamorous: establish what the organisation actually holds. Collateral loans have been an appealing wrapper precisely because one line on Schedule BA could contain very different economics — a conservatively secured mortgage participation and a loan against a residual tranche carried the same charge. They no longer do. An inventory that classifies each position by its underlying collateral type, current loan-to-value, and overcollateralization level is the foundation for everything else, and for most organisations it does not exist yet.

Then solve the data problem before the actuarial one

The relief in the new framework is not automatic. It is earned with evidence: independent fair-value verification of collateral, current overcollateralization calculations, and the ability to refresh both. That is a data and vendor question as much as a capital question. Positions that are economically well secured but cannot demonstrate it will be charged as if they were not. The gap between the capital an insurer could hold and the capital it will hold is, in many cases, simply a documentation gap — and closing it takes lead time that the year-end 2026 CLO effective date has already started consuming.

Forecast under both dates

The two changes take effect a year apart. That staggering is useful: CLO factors bite at year-end 2026, collateral-loan treatment at year-end 2027. A capital forecast that models both dates — and the interaction between them for insurers holding both asset types — turns a compliance exercise into a planning one. It also surfaces the quieter question of whether investment guidelines written around the old flat charge still say what the organisation means. Guidelines that treated all collateral loans as interchangeable were rational under a uniform charge. They are stale under a differentiated one.

Reprice the reinsurance conversation

This is the step most likely to be missed, because it sits between departments. Collateral supporting reinsurance — trust assets, funded arrangements, the portfolios standing behind letters of credit — is selected by someone, and that someone now faces different capital consequences for different choices. A cedent or fronting carrier whose reinsurer holds capital-inefficient assets should expect that inefficiency to surface somewhere: in pricing, in collateral substitutions, in the durability of capacity. The prudent move is to ask counterparties directly how their portfolios respond to the new factors, before renewal season answers the question for you.

What this means for captives specifically

Captive boards are not spectators here. Captives hold collateral loans to affiliates, invest trust assets, and depend on fronting carriers whose reinsurers are directly affected. The new framework effectively pays for two things captives can control: demonstrable overcollateralization and independent valuation. Both are governance capabilities before they are investment outcomes. A captive that can evidence the quality of what secures its lending and its collateral is now, quite literally, cheaper to run — and one that cannot should expect its regulators, fronting partners, and auditors to notice the difference. For the wider regulatory backdrop, we keep a running Captive Regulatory Tracker, and the Academy's deeper dive on solvency regimes and captive capital covers the machinery underneath.

The through-line

The old framework asked whether an asset was eligible. The new one asks whether its economics can be demonstrated. That shift — from technical eligibility toward demonstrated resilience — is the defining move in insurance capital oversight right now, and it is not confined to RBC. Part II of this series takes up its sharpest current expression: what happens when the capital standing behind insurance obligations turns out to be connected, economically, to the very risks it secures.

Educational commentary on insurance capital and regulatory developments, current as at August 2026 and subject to change. Not insurance, actuarial, tax, legal, or financial advice for any specific organisation.